Datapoint: GSK Scores Full Approval for Jemperli

The FDA on June 6 granted full approval to GSK’s Jemperli (dostarlimab) for the treatment of mismatch repair-deficient (dMMR) recurring or advanced endometrial cancer, in combination with chemotherapy. The agency originally granted the immune checkpoint inhibitor accelerated approval in April 2021. For the treatment of endometrial cancer, Jemperli — which is administered as an intravenous infusion — currently holds covered or better status for 88% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 6/7/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 7

Datapoint: FDA Approves Jemperli as Frontline Endometrial Cancer Treatment

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 21

Datapoint: Could Florida Be Poised to Expand Medicaid?

Read More
a-doctor-video-chatting
February 11

New York Medicaid Insurer Hopes Virtual Care Will Boost Access

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today